Microscope and vial

Gastrointestinal Stromal Tumors (GIST) are one of the most common forms of sarcoma.  There may be as many as 4,000 new GIST patients per year in the United States.  SARC, alongside sarcoma research leaders like Cogent Biosciences, Dana Farber Cancer Institute and The Life Raft Group, is committed to collaborating to advance treatment options for GIST patients.  Click here to learn about trends in GIST research and stay connected with SARC for an exciting announcement!

Back to top